TD Cowen maintains Twist Bioscience at Buy, lowers price target to $137 from $190
TD Cowen kept Twist Bioscience's rating at Buy but reduced its price target to $137 from $190, a 27.9% cut. This implies a 19.9% upside from the Nov 12 close of $114.22, according to the firm.
How this was made

The 30-second read
Why it matters
The downgrade could trigger short-term downside pressure but the Buy rating may limit the sell-off.
Market read
Analyst target cut is a modest catalyst for TWST, offering a medium‑term trading signal.
What to watch
Potential upcoming product launches or partnerships not reflected in the target.
Background
TD Cowen maintains a Buy rating but reduces the price target, reflecting a shift in expectations.
Ticker impact
TD Cowen lowered Twist Bioscience's price target to $137 from $190, indicating a downgrade.
likely pressure as the market prices in the lower target
Target reduction signals weaker expectations, which can prompt short-term selling.
Market effects
May affect other synthetic biology and biotech stocks as analysts reassess valuations.
Limited to US biotech sector.
Low global impact.
Counterpoint
Some investors may view the cut as an overreaction and see buying opportunity.
Key entities
- CompanyTwist Bioscience
Synthetic biology company listed on NASDAQ.
- AnalystTD Cowen
Equity research firm providing the rating and target.


